DOVPRELA

This brand name is authorized in Estonia, France, Croatia, Italy, Lithuania, Poland

Active ingredients

The drug DOVPRELA contains one active pharmaceutical ingredient (API):

1 Pretomanid UNII 2XOI31YC4N - PRETOMANID

The mechanism of action of pretomanid is thought to involve inhibition of the synthesis of cell wall lipids under aerobic conditions and generation of reactive nitrogen species under anaerobic conditions. Reductive activation of pretomanid by a mycobacterial deazaflavin (F420)-dependent nitro-reductase is required for activity under both aerobic and anaerobic conditions. Read about Pretomanid

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DOVPRELA Tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J04AK08		J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AK Other drugs for treatment of tuberculosis
Discover more medicines within J04AK08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1824746, 1824757, 1824768, 1824779, 1824825, 1840407
Country: FR	Base de données publique des médicaments	Identifier(s): 63915869
Country: IT	Agenzia del Farmaco	Identifier(s): 048955013, 048955025, 048955037, 048955049, 048955052
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090966, 1090967, 1090968, 1090969, 1090999
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100439106